SPC | Time Point | Age (y) | Sex | Rx | Coinfection | CD4 | CD8 | VL | HIV Tetramer | TRAF1 Increased? |
---|---|---|---|---|---|---|---|---|---|---|
16123 | Baseline | 50 | M | Yes | No | 364 | 699 | <40 | A2 (SL9) | Yes |
Week 12 | 981 | 1335 | <40 | |||||||
31209 | Baseline | 49 | M | Yes | No | 263 | 1118 | <40 | A2 (SL9, ILKE) | No |
Week 12 | 661 | 2663 | <40 | |||||||
31427 | Baseline | 30 | M | Yes | No | 274 | 293 | <40 | A2 (SL9, ILKE) | Yes |
Week 12 | 836 | 768 | <40 | |||||||
16206 | Baseline | 38 | M | Yes | No | 191 | 699 | <40 | B7 (FPRI) | Yes |
Week 12 | 441 | 1648 | <40 | |||||||
31210 | Baseline | 32 | M | Yes | No | 162 | 604 | <40 | A2 (SL9) | No |
Week 12 | 485 | 1292 | <40 | |||||||
31231 | Baseline | 42 | M | Yes | No | 365 | 588 | <40 | A2 (SL9) | No |
Week 12 | 838 | 979 | <40 | |||||||
31208 | Baseline | 41 | M | Yes | No | 191 | 350 | <40 | B7 (FPRI) | No |
Week 12 | 662 | 1342 | <40 | |||||||
31213 | Baseline | 45 | M | Yes | No | 457 | 342 | <40 | B7 (FPRI) | Yes |
Week 12 | 747 | 929 | <40 | |||||||
31206 | Baseline | 53 | M | Yes | No | 338 | 591 | <40 | B57 (KAFS) | No |
Week 12 | 451 | 729 | <40 | |||||||
16207 | Baseline | 55 | M | Yes | No | 155 | 1553 | <40 | B57 (KAFS) | Yes |
Week 12 | 282 | 2435 | <40 |
Summary of patient data including age, sex, treated (Rx), and CD4 and CD8 T cell counts before and 12 wk after first IL-7 treatment. HIV tetramer indicates population identified in the study participants. A2 epitopes were SL9 or ILKE, B7 (FPRI), and B57 (KAFS) as described in Materials and Methods; where both are listed, study participants had both HIV-specific CD8 T cell populations.
M, male; SPC, study participant code; VL, viral load.